Last Update 11 Jun 26

HSIC: Dental Demand And Cost Controls Are Expected To Support Balanced Outlook

Analysts have raised their average price target on Henry Schein to $100. They cite recent commentary around generally healthy dental markets, margin gains in Q1 driven by cost reductions, and a view that the stock has found technical support.

Analyst Commentary

Recent research on Henry Schein highlights a mix of optimism around the core dental business and cost control, alongside more cautious views on medical trends and valuation risk.

Bullish Takeaways

Bullish analysts point to generally healthy dental markets, which they see as an important support for revenue and earnings quality.
Cost reduction efforts in Q1, which contributed to margin expansion, are viewed as evidence that management is focused on execution and profitability rather than just top line growth.
The view that the stock has found significant technical support feeds into the case that recent price levels may already reflect a lot of prior concerns.
The upgrade to a US$100 price target is framed as being based on a combination of operational efficiency and stable end markets, which bullish analysts see as supportive for the current valuation framework.

Bearish Takeaways

Bearish analysts remain cautious on the medical segment, where low growth in Q1 raised questions about competitive pressures and the durability of that part of the business.
Several firms have reduced their price targets in recent months, which signals ongoing debate about how much earnings power should be reflected in the stock.
Some coverage has been initiated with more neutral views, underscoring concerns that upside may depend on consistent execution on margins and growth rather than just healthy dental demand.
The reliance on a light flu season to explain softer medical trends highlights a risk that volumes could stay uneven if similar conditions repeat, which can affect how investors think about the stock’s growth profile.

What's in the News

Henry Schein reported Q1 2026 adjusted EPS of US$1.32, which was 14.8% higher year over year and ahead of analyst expectations, with net sales of US$3.37b, supported by internal growth across dental, medical distribution, and value added services segments. (Source: Henry Schein Reports Strong Q1 2026 Results with 14.8% EPS Growth and Raises Sales Guidance)
The company reaffirmed its full year 2026 outlook, guiding to total sales growth of 3% to 5% and non GAAP diluted EPS of US$5.23 to US$5.37. (Source: Henry Schein Reports Strong Q1 2026 Results with 14.8% EPS Growth and Raises Sales Guidance)
Management highlighted progress on a value creation plan that targets a potential US$125 million net run rate operating income improvement by the end of 2026, supported by steady U.S. dental demand and new offerings such as AI enabled tools and the Curodont product. (Source: Henry Schein Sees Steady Dental Demand, $125M Profit Lift by 2026)
Henry Schein reaffirmed guidance that 2026 total sales growth is expected to be approximately 3% to 5% over 2025. (Source: Corporate guidance filing)
Between December 28, 2025 and March 28, 2026, the company repurchased 1,609,986 shares, about 1.39% of shares, for US$125 million, bringing total buybacks under the December 13, 2018 authorization to 43,297,237 shares, about 32.76%, for US$3,095.31 million. (Source: Buyback tranche update)

Valuation Changes

Fair Value: $87.21 is unchanged, indicating no adjustment to the modeled intrinsic value per share in this update.
Discount Rate: 7.28% has risen slightly to 7.29%, reflecting a very small increase in the required return used in the valuation.
Revenue Growth: 3.76% is essentially flat, with only a minimal numerical adjustment in the projected growth rate.
Net Profit Margin: 4.22% is also effectively unchanged, with only a minor rounding level shift in the margin assumption.
Future P/E: 16.06x has edged slightly higher to 16.07x, signaling a very small change in the valuation multiple applied to future earnings.

2 views

Key Takeaways

Focus on high-margin segments, digital transformation, and operational efficiencies is expected to boost margins and earnings growth.
Demographic shifts and industry consolidation are likely to drive sustained demand and enhance customer loyalty in key markets.
Margin pressures from competitive pricing, staffing constraints, regulatory hurdles, and execution risks could limit revenue growth and profitability despite stabilization efforts in key business areas.

Catalysts

About Henry Schein

Provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.What are the underlying business or industry changes driving this perspective?

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments-supporting structurally higher gross margins and likely driving earnings expansion.
Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Henry Schein is actively pursuing operational efficiencies-including $100M+ cost savings run-rate by end of 2025 and further value creation initiatives led by KKR's Capstone-which are expected to lower operating expenses and drive net margin improvement from 2026 onward.
Continued expansion of the company's Home Solutions platform to meet increased demand for at-home healthcare, coupled with robust demographic drivers from an aging global population, are anticipated to support sustained volume growth in core distribution and specialty lines, providing a foundation for long-term revenue growth.
Dental and medical practice consolidation is increasing client reliance on integrated supply, technology, and value-added service partners like Henry Schein, enhancing share gains and customer stickiness across both the U.S. and international markets-with positive implications for top-line growth and earnings stability.

Henry Schein Earnings and Revenue Growth

Henry Schein Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Henry Schein's revenue will grow by 3.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.0% today to 4.2% in 3 years time.
Analysts expect earnings to reach $630.1 million (and earnings per share of $5.24) by about June 2029, up from $395.0 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.1x on those 2029 earnings, down from 22.7x today. This future PE is lower than the current PE for the US Healthcare industry at 22.7x.
Analysts expect the number of shares outstanding to decline by 6.06% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.29%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent competitive pricing pressures, especially in key categories like gloves (where pricing remains very competitive and still below previous year levels), could continue to weigh on distribution gross margins, reducing profitability and potentially hindering earnings growth even as volume stabilizes.
Flat to modest dental patient traffic and ongoing staffing shortages (notably in hygienists and office support) are constraining underlying volume growth in the core dental business globally, which limits organic revenue expansion and exposes results to macroeconomic or reimbursement shocks in key markets.
Greater customer price sensitivity due to tariffs and the potential for large DSO/group customers to actively RFP portions of their business places greater bargaining power with customers, risking margin compression and slower top-line growth if Henry Schein cannot fully offset price concessions with its owned brands or value-added services.
International expansion, while producing some bright spots, faces country-specific regulatory challenges (e.g. recent law changes in France), currency volatility, and localized competition, all of which could restrict anticipated revenue diversification and net earnings contribution from outside the U.S.
The multi-year leadership transition and implementation of cost-saving/value creation initiatives with KKR/consulting partners carry significant execution risk; delays, integration hurdles, or cultural disruption could impair near-term efficiency gains, and if technology or AI investments lag or under-deliver, Henry Schein could lose share to more innovative or nimble competitors, pressuring long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $87.21 for Henry Schein based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of just $64.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $14.9 billion, earnings will come to $630.1 million, and it would be trading on a PE ratio of 16.1x, assuming you use a discount rate of 7.3%.
Given the current share price of $78.85, the analyst price target of $87.21 is 9.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Henry Schein?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook